MX2021014139A - Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f. - Google Patents

Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.

Info

Publication number
MX2021014139A
MX2021014139A MX2021014139A MX2021014139A MX2021014139A MX 2021014139 A MX2021014139 A MX 2021014139A MX 2021014139 A MX2021014139 A MX 2021014139A MX 2021014139 A MX2021014139 A MX 2021014139A MX 2021014139 A MX2021014139 A MX 2021014139A
Authority
MX
Mexico
Prior art keywords
compositions
pyridinoylpiperidine
methods related
ht1f agonists
ht1f
Prior art date
Application number
MX2021014139A
Other languages
English (en)
Inventor
Raymond D Skwierczynski
Emma Sharp
Brigida Allieri
Paul Fagan
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021014139(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of MX2021014139A publication Critical patent/MX2021014139A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona nuevos pseudopolimorfos de la sal de hemisuccinato de 2,4,6trifluoro-N-[6-(1-metil-piperidin-4-c arbonil)-piridin-2-il]-benzamida que son útiles en composiciones farmacéuticas, por ejemplo, para el tratamiento y prevención de la cefalea migrañosa.
MX2021014139A 2016-12-06 2017-12-05 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f. MX2021014139A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430662P 2016-12-06 2016-12-06
PCT/US2017/064652 WO2018106657A1 (en) 2016-12-06 2017-12-05 Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Publications (1)

Publication Number Publication Date
MX2021014139A true MX2021014139A (es) 2022-05-24

Family

ID=60972336

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021014139A MX2021014139A (es) 2016-12-06 2017-12-05 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
MX2019006520A MX2019006520A (es) 2016-12-06 2017-12-05 Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019006520A MX2019006520A (es) 2016-12-06 2017-12-05 Composiciones y metodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.

Country Status (38)

Country Link
US (1) US11053214B2 (es)
EP (1) EP3551617B1 (es)
JP (3) JP2020500936A (es)
KR (3) KR20230008257A (es)
CN (3) CN115385894A (es)
AU (1) AU2017373784B2 (es)
BR (1) BR112019010934A2 (es)
CA (1) CA3043772C (es)
CL (1) CL2019001426A1 (es)
CO (1) CO2019005290A2 (es)
CR (1) CR20190251A (es)
CY (1) CY1124540T1 (es)
DK (1) DK3551617T3 (es)
DO (1) DOP2019000139A (es)
EA (1) EA201991112A1 (es)
EC (1) ECSP19040190A (es)
ES (1) ES2889476T3 (es)
HR (1) HRP20211557T1 (es)
HU (1) HUE056820T2 (es)
IL (1) IL266598B2 (es)
JO (1) JOP20190129B1 (es)
LT (1) LT3551617T (es)
MA (1) MA52920B1 (es)
MD (1) MD3551617T2 (es)
MX (2) MX2021014139A (es)
MY (1) MY196855A (es)
NZ (1) NZ752906A (es)
PE (1) PE20191134A1 (es)
PH (1) PH12019501252A1 (es)
PL (1) PL3551617T3 (es)
PT (1) PT3551617T (es)
RS (1) RS62415B1 (es)
SI (1) SI3551617T1 (es)
TN (1) TN2019000174A1 (es)
TW (1) TWI671290B (es)
UA (1) UA124433C2 (es)
WO (1) WO2018106657A1 (es)
ZA (1) ZA201903449B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119319A1 (es) * 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
WO2022236004A1 (en) 2021-05-07 2022-11-10 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
KR101697801B1 (ko) 2009-04-02 2017-01-18 코루시드 파마슈티컬즈 인코포레이티드 2,4,6-트리플루오로-ｎ-〔6-（1-메틸-피페리딘-4-카르보닐）-피리딘-2-일］-벤즈아미드의 조성물
CA2795062A1 (en) * 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
EP2714040A1 (en) 2011-06-01 2014-04-09 Concit Pharma ApS Combinations of serotonin receptor agonists for treatment of movement disorders
CN113149959A (zh) 2016-07-15 2021-07-23 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
CO2019005290A2 (es) 2019-05-31
DOP2019000139A (es) 2019-08-15
CY1124540T1 (el) 2022-07-22
KR20230008257A (ko) 2023-01-13
MA52920B1 (fr) 2021-11-30
MD3551617T2 (ro) 2021-12-31
SI3551617T1 (sl) 2021-11-30
MX2019006520A (es) 2019-08-21
JOP20190129A1 (ar) 2019-05-29
IL266598B2 (en) 2024-05-01
BR112019010934A2 (pt) 2019-10-01
PL3551617T3 (pl) 2021-12-20
PT3551617T (pt) 2021-10-04
IL266598B1 (en) 2024-01-01
JP2020500936A (ja) 2020-01-16
JOP20190129B1 (ar) 2023-03-28
CN115385894A (zh) 2022-11-25
PH12019501252A1 (en) 2019-12-02
AU2017373784A1 (en) 2019-05-16
JP2023123678A (ja) 2023-09-05
IL266598A (en) 2019-07-31
KR20190075130A (ko) 2019-06-28
ES2889476T3 (es) 2022-01-12
TN2019000174A1 (en) 2020-10-05
CR20190251A (es) 2019-08-26
CN110291079A (zh) 2019-09-27
AU2017373784B2 (en) 2020-04-23
TWI671290B (zh) 2019-09-11
NZ752906A (en) 2021-07-30
WO2018106657A1 (en) 2018-06-14
CL2019001426A1 (es) 2019-10-11
CA3043772C (en) 2022-06-07
RS62415B1 (sr) 2021-10-29
LT3551617T (lt) 2021-10-11
MY196855A (en) 2023-05-05
JP2022000451A (ja) 2022-01-04
US20200087279A1 (en) 2020-03-19
EP3551617B1 (en) 2021-08-11
HUE056820T2 (hu) 2022-03-28
CA3043772A1 (en) 2018-06-14
ZA201903449B (en) 2021-02-24
EA201991112A1 (ru) 2019-10-31
HRP20211557T1 (hr) 2022-01-07
US11053214B2 (en) 2021-07-06
ECSP19040190A (es) 2019-08-30
DK3551617T3 (da) 2021-09-13
MA52920A (fr) 2021-04-28
KR20210102497A (ko) 2021-08-19
TW201833097A (zh) 2018-09-16
CN115385893A (zh) 2022-11-25
PE20191134A1 (es) 2019-09-02
EP3551617A1 (en) 2019-10-16
UA124433C2 (uk) 2021-09-15

Similar Documents

Publication Publication Date Title
PH12020550622A1 (en) Kras g12c inhibitors
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2018013983A (es) Inhibidores g12c de kras.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
EA033163B1 (ru) Ингибиторы глутаминазы
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
PH12016501619A1 (en) Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
TN2018000359A1 (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide.
PH12019501252A1 (en) Compositions and methods related to pyridinoylpiperidine 5-htif agonists
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX2017007318A (es) Metodos de prevencion, reduccion o tratamiento de degeneracion macular.
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.